Can a Game-Like app retrain your brain to beat depression?
NCT ID NCT05601362
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This study tests a gamified mobile app designed to reduce symptoms of depression and rumination (repetitive negative thinking). People with moderate or greater depression use the app for four weeks, completing daily surveys and weekly assessments. The app uses attention bias modification training to gently shift focus away from negative stimuli. The goal is to see if this digital tool can improve mood and thinking patterns.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Gamified Attention Bias Modification (GAMBT) mobile app
- What this could lead to
- If effective, this app could offer a low-cost, accessible tool to help people with depression reduce symptoms and repetitive negative thinking.
- What could go wrong
- This is a small, early-stage study with no control for long-term effects. The intervention may not outperform the placebo version, and results may not generalize to all people with depression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
110 people
The number who actually took part.
- Started
-
Mar 2023
- Finished
-
Aug 2023
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 45 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * able and willing to provide informed consent; * fluent in English; * normal or corrected-to-normal vision * moderate or greater depression symptoms (defined as greater than or equal to 10 on the PHQ-8); * attention bias for negative stimuli (operationalized as greater than an average of 6500 ms of dwell time on sad faces in an attention bias task); * stable psychiatric and neurological medication usage. * access to a smartphone for downloading the app and a laptop or desktop computer to complete the weekly assessments Exclusion Criteria: * recent heavy alcohol use defined as a score of 2 or higher on the PDSQ * past or present comorbidity of other serious mental illness (e.g., schizophrenia, substance use disorder, bipolar disorder, etc.) * previous experience with gamified attention bias modification app
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Depression are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mary Eileen McNamara
Austin, Texas, 78712, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- The dynamic mechanism of mindfulness intervention for emotional distress (MIED) based on ecological moment measurement
- Role of self-focused attention in depression
- Project QUIT+: adapting and testing a smoking cessation intervention for transgender and gender expansive individuals
- Can a nudge toward healthy habits boost an online depression and anxiety program?
- Can brain activity reveal why some people with depression lose motivation and pleasure?
- A brain stimulation trial aims to rewire the circuit behind depression